FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2114392365> ?p ?o ?g. }

• W2114392365 endingPage "553" @default.
• W2114392365 startingPage "547" @default.
• W2114392365 abstract "To develop recommendations for TNFalpha antagonist therapy in patients with spondyloarthropathies.The Delphi consensus procedure was used to select questions, to which evidence-based answers were sought in the literature. Expert opinion was used when needed to estimate the risks and benefits of TNFalpha antagonists. TNFalpha antagonists exert potent antiinflammatory effects but fail to provide a definitive cure.Recommendations were developed for patients with ankylosing spondylitis (AS) or psoriatic arthritis (PsA). The following criteria for TNFalpha antagonist therapy were selected: definitive diagnosis of AS or PsA, active disease for at least 4 consecutive weeks documented during two physician visits, overall physician's assessment of disease activity>/=4/10 and BASDAI>/=4/10 in axial disease or at least three tender and swollen joints in peripheral disease, failure to respond adequately to at least three nonsteroidal antiinflammatory drugs given in optimal dosages for at least 3 months in axial disease or at least one disease-modifying antirheumatic drug (methotrexate, leflunomide, sulfasalazine) for at least 4 months, with local glucocorticoid injections if appropriate, in peripheral disease. Effectiveness and safety should be evaluated by a rheumatologist. The frequency of monitoring depends on the drug. Lack of effectiveness should be defined as inadequate improvement after 6-12 weeks, with a less than two-point decrease in the BASDAI in axial disease or a less than 30% decrease in the tender and swollen joint counts in peripheral disease.These clinical practice recommendations should help rheumatologists in their everyday decisions regarding the use of TNFalpha antagonist therapy in patients with AS or PsA." @default.
• W2114392365 created "2016-06-24" @default.
• W2114392365 creator A5005178337 @default.
• W2114392365 creator A5005853606 @default.
• W2114392365 creator A5008811878 @default.
• W2114392365 creator A5015032522 @default.
• W2114392365 creator A5017486273 @default.
• W2114392365 creator A5022620505 @default.
• W2114392365 creator A5031211618 @default.
• W2114392365 creator A5032316254 @default.
• W2114392365 creator A5047641886 @default.
• W2114392365 creator A5049309445 @default.
• W2114392365 creator A5051196993 @default.
• W2114392365 creator A5057460230 @default.
• W2114392365 creator A5068131579 @default.
• W2114392365 creator A5073579921 @default.
• W2114392365 creator A5076446601 @default.
• W2114392365 creator A5089483834 @default.
• W2114392365 date "2006-10-01" @default.
• W2114392365 modified "2023-10-09" @default.
• W2114392365 title "TNFα antagonist therapy in ankylosing spondylitis and psoriatic arthritis: recommendations of the French Society for Rheumatology" @default.
• W2114392365 cites W1804977839 @default.
• W2114392365 cites W1966756689 @default.
• W2114392365 cites W1968958817 @default.
• W2114392365 cites W1969693005 @default.
• W2114392365 cites W1976217778 @default.
• W2114392365 cites W1978655912 @default.
• W2114392365 cites W1981498496 @default.
• W2114392365 cites W1983577477 @default.
• W2114392365 cites W1986200978 @default.
• W2114392365 cites W1994277369 @default.
• W2114392365 cites W2006704004 @default.
• W2114392365 cites W2018697945 @default.
• W2114392365 cites W2027454708 @default.
• W2114392365 cites W2037976962 @default.
• W2114392365 cites W2093698914 @default.
• W2114392365 cites W2094124191 @default.
• W2114392365 cites W2097730524 @default.
• W2114392365 cites W2100566012 @default.
• W2114392365 cites W2101695974 @default.
• W2114392365 cites W2101965770 @default.
• W2114392365 cites W2102829569 @default.
• W2114392365 cites W2112521624 @default.
• W2114392365 cites W2114488753 @default.
• W2114392365 cites W2121157358 @default.
• W2114392365 cites W2124332978 @default.
• W2114392365 cites W2134387478 @default.
• W2114392365 cites W2149168537 @default.
• W2114392365 cites W2165062595 @default.
• W2114392365 cites W2166606029 @default.
• W2114392365 cites W2168698481 @default.
• W2114392365 cites W4211046919 @default.
• W2114392365 cites W4241877965 @default.
• W2114392365 cites W4247296587 @default.
• W2114392365 cites W4252987188 @default.
• W2114392365 doi "https://doi.org/10.1016/j.jbspin.2006.02.005" @default.
• W2114392365 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16843030" @default.
• W2114392365 hasPublicationYear "2006" @default.
• W2114392365 type Work @default.
• W2114392365 sameAs 2114392365 @default.
• W2114392365 citedByCount "33" @default.
• W2114392365 countsByYear W21143923652012 @default.
• W2114392365 countsByYear W21143923652015 @default.
• W2114392365 crossrefType "journal-article" @default.
• W2114392365 hasAuthorship W2114392365A5005178337 @default.
• W2114392365 hasAuthorship W2114392365A5005853606 @default.
• W2114392365 hasAuthorship W2114392365A5008811878 @default.
• W2114392365 hasAuthorship W2114392365A5015032522 @default.
• W2114392365 hasAuthorship W2114392365A5017486273 @default.
• W2114392365 hasAuthorship W2114392365A5022620505 @default.
• W2114392365 hasAuthorship W2114392365A5031211618 @default.
• W2114392365 hasAuthorship W2114392365A5032316254 @default.
• W2114392365 hasAuthorship W2114392365A5047641886 @default.
• W2114392365 hasAuthorship W2114392365A5049309445 @default.
• W2114392365 hasAuthorship W2114392365A5051196993 @default.
• W2114392365 hasAuthorship W2114392365A5057460230 @default.
• W2114392365 hasAuthorship W2114392365A5068131579 @default.
• W2114392365 hasAuthorship W2114392365A5073579921 @default.
• W2114392365 hasAuthorship W2114392365A5076446601 @default.
• W2114392365 hasAuthorship W2114392365A5089483834 @default.
• W2114392365 hasConcept C126322002 @default.
• W2114392365 hasConcept C1862650 @default.
• W2114392365 hasConcept C198451711 @default.
• W2114392365 hasConcept C2775905006 @default.
• W2114392365 hasConcept C2776260265 @default.
• W2114392365 hasConcept C2776661782 @default.
• W2114392365 hasConcept C2777077863 @default.
• W2114392365 hasConcept C2777138892 @default.
• W2114392365 hasConcept C2777226972 @default.
• W2114392365 hasConcept C2777402515 @default.
• W2114392365 hasConcept C2777453003 @default.
• W2114392365 hasConcept C2777575956 @default.
• W2114392365 hasConcept C2779134260 @default.
• W2114392365 hasConcept C2779383735 @default.
• W2114392365 hasConcept C2780132546 @default.
• W2114392365 hasConcept C2780479503 @default.
• W2114392365 hasConcept C71924100 @default.
• W2114392365 hasConceptScore W2114392365C126322002 @default.

• next